Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090091 | 0.92 | MIF (0.55) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL3091389 | 0.92 | MIF (0.55) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL3088071 | 0.91 | MIF (0.58) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL3095181 | 0.91 | MIF (0.53) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL3095179 | 0.91 | MIF (0.56) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL4553184 | 0.87 | MIF (0.56) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL3078112 | 0.84 | MIF (0.54) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL1097801 | 0.83 | MIF (0.58) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL1098096 | 0.83 | MIF (0.55) | MIFNOTUMF10HPGDMAPK1 | |
| SCHEMBL3091423 | 0.83 | MIF (0.62) | MIFNOTUMF10HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | claimed |
| EP-2114928-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | claimed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | claimed |
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7696352-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696352-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2114928-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | MIF 792/4885NOTUM 346/4885F10 10/4885 |
| US-20100234352-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MIF 792/4885NOTUM 346/4885F10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.